9, 2024 /PRNewswire/ -- Belong.Life, a leading global provider of AI-powered patient education and support solutions, announced today that the European Society For Medical Oncology (ESMO ...
ROCKVILLE, Md. and SUZHOU, China, Sept. 13, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical ...
New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with ...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...
The trial compares Eli Lilly’s lutetium zadavotide guraxetan with Astellas’s Xtandi (enzalutamide) or Janssen’s Zytiga ...
Patients with advanced SSC of the anal canal have a marked survival benefit when immunotherapy is added to standard-of-care ...
Indeed, the global oncology community trusts ESMO to disseminate the latest results of cancer research. Why? Because it is ...
NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...
The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona this weekend – ...
But sex health assessments are not yet part of oncological clinical practice, despite studies showing that infertility and ...
At ESMO, Multiple Enhertu Studies Highlight Challenges of Selecting, Managing Breast Cancer Patients
Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback